Bad news trumps good for MA, AstraZeneca

In a good news/bad news scenario, Massachusetts is getting the bad news first: AstraZeneca will be cutting 113 jobs at its manufacturing plant in Westborough, about 30 miles west of Boston. Cuts begin in October as the big pharma fights generics-maker Apotex, which is producing a knockoff of AZ's Pulmicort Respules asthma drug, says the Boston Globe.

The good news for the Bay State: AstraZeneca expects to open its expanded research facilities in Waltham, a Boston suburb, in November. The expansion brings the facility to 514,000 square feet from its former 380,000.

And some bad news for AZ (and MedImmune, GlaxoSmithKline and Novartis): swine-flu vaccine developer Serum Institute of India says it is "likely" to sell its vaccine for "one-fifth to one-tenth the cost of similar vaccines being made in Western economies," says a Wall Street Journal report.

- here's the Boston Globe article
- read the Wall Street Journal item

Suggested Articles

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.